Hong Kong-based healthcare-focused investment group Ally Bridge Group (ABG) has led an over-subscribed $65 million financing for Pulmonx Corporation, a California-based company in diagnostic and therapeutic pulmonary device technologies, according to a statement.
Pulmonx is focused on developing life-changing technologies that improve the lives of patients suffering from Chronic Obstructive Pulmonary Disease (COPD).